today issued the following update letter from G6’s President and Chief Executive Officer (“CEO”), Daniel Stolyarov, to the Company’s shareholders:
today announced the results of the
antimicrobial efficacy test on a prototype of G6’s proprietary graphene-based air purifier (the
“Lab Test”) conducted by a US-based microbiological laboratory of The Intertek Group plc. The
test showed that the concentration of pathogenic microorganisms present in the testing chamber
was reduced by 99.9% (“Test Results”) over the duration of the experiment.
today announced the closing of the previously announced acquisition of all membership interests (the “Transaction”) of GX Technologies, LLC (“GX Technologies” or “GX”), effective August 25, 2021 (the “Closing Date”).
is pleased to announce that it has executed a definitive purchase agreement (the “Agreement”) to formalize and close the previously announced acquisition (the “Transaction”) of all membership interests of GX Technologies, LLC (“GX Technologies”). Pursuant to the terms of the Agreement, the consideration paid for the membership interests of GX Technologies is 25,000,000 common shares (the “Consideration Shares”) of G6 at a deemed price of C$0.20 per common share of the Company.
… finalized the research and development project to develop graphene-based composite materials for marine vessel applications (the “Project”) with a private Singaporean company (“Partner”). The Partner has accepted G6’s final research report and the Company expects to receive a final payment from the Partner of approximately $117,500 US Dollars, or $161,400 Singapore Dollars. During the Project, G6 successfully developed two formulations for graphene-enhanced resins for fiberglass and carbon fiber marine composites.